Risk Score Helps Identify Patients With CH at High Risk of Myeloid Malignancy
Clonal hematopoiesis (CH) is relatively common, with up to 15% of adults age 60 and older estimated to have one of two CH conditions: CH of indeterminate potential (CHIP) and clonal cytopenia of ...
Luspatercept Effective for the Treatment of Anemia in Patients with Myelofibrosis
Research continues to support luspatercept (LUSPA) as a treatment for anemia and transfusion burden in patients living with myelofibrosis ...
Phase III COMMANDS Trial Explores Luspatercept as First-line Agent in MDS
Results from the phase 3 COMMANDS trial indicate luspatercept may more effectively treat anemia than erythropoiesis-stimulating agents (ESAs) r ...
Imetelstat May Provide New Treatment Option for MDS Refractory to ESAs
Imetelstat may provide a new treatment approach in patients with lower-risk myelodysplastic syndromes (MDS) who require regular transfusions to treat anemia but are refractory or relapsed to erythropoiesis-stimulating agents ...
Relationship of MDS, Vulnerability, and Health-Related Quality of Life
Research suggests that although patients with lower-risk myelodysplastic syndromes (MDS) tend to experience better health-related quality of life (HRQoL), for “vulnerable” patients ...
Iron Regulation Key to Polycythemia Vera
Regulation of iron homeostasis is critical in polycythemia vera (PV), according to findings stemming from an extensive genetic analysis and preclinical experiments ...
Integrated Care, Wider Donor Sources Can Boost Transplant Access for Patients With AL, MDS
Integrating hematopoietic cell transplantation (HCT) care and non-transplant care, as well as using haploidentical donors and other donor types, can boost access to transplantation and reduce racial disparities ...
Diagnostic Tool Can Help Discern MDS Among Patients With Cytopenias
Predicting which patients with cytopenias have a myeloid malignancy and which have myelodysplastic syndromes (MDS) may be possible using a tool developed with data from the National MDS Natural History Study ...
The Value of AlloHCT in Patients With Blast Phase Myeloproliferative Neoplasms (BP-MPN)
In recent years, survival outcomes have improved in patients with blast phase (BP) transformation of myeloproliferative neoplasms (MPNs) who undergo allogeneic hematopoietic cell transplant ...
Phase I/II Study Results in 87% Overall Response Rate With Venetoclax, Azacitidine Combo in High-Risk MDS
The use of the BCL-2 inhibitor venetoclax combined with hypomethylating agent azacitidine had encouraging clinical activity in patients with high-risk myelodysplastic syndromes...
